Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05051436 · ClinicalTrials.gov registry record · Phase 4
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
A Phase 4 study of Obesity and PreDiabetes, sponsored by Philip Kern.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT05051436: Recruiting Phase 4 study of Obesity and PreDiabetes, sponsored by Philip Kern.
NCT05051436 is a Phase 4 study of Obesity and PreDiabetes that is actively recruiting participants, run by Philip Kern. The registered enrollment target is 96 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05051436, a Phase 4 study of Obesity and PreDiabetes, is actively recruiting participants, sponsored by Philip Kern.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
Primary Outcome
Participants will complete a standard oral glucose tolerance test using 75 g of glucose at baseline and blood glucose will be measured.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mirabegron 50 MG
- DRUG Tadalafil 10 MG
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2026-08 |
| Phase | Phase 4 |
What NCT05051436 shows while recruiting
NCT05051436 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05051436 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT05051436 about?
NCT05051436 is a clinical study titled "The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics". The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will c...
What is the current status of trial NCT05051436?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 96 participants. The study started on 2021-12-13. Estimated completion is 2026-08.
What conditions does trial NCT05051436 study?
This clinical trial studies the following conditions: Obesity, PreDiabetes.
What interventions are being tested in trial NCT05051436?
The interventions under investigation include: Placebo (DRUG), Mirabegron 50 MG (DRUG), Tadalafil 10 MG (DRUG).
Who is sponsoring clinical trial NCT05051436?
This trial is sponsored by Philip Kern, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05051436 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05051436's enrollment target sits among peer trials
96 504th of 1053 higher than 545 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
-
A Study of a Novel Precision Medicine Approach For Obesity
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI